Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Companies(5)
BioAge
BioAge is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases by targeting the biology of human aging.
insitro
Insitro is a data-driven drug discovery company leveraging machine learning and high-throughput biology to create AI therapeutics.
Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage biotech company decoding biology by running millions of experiments and applying AI to accelerate drug discovery.
Tempus AI
Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research by aggregating and analyzing multimodal healthcare data.
XtalPi
XtalPi is an AI drug discovery company leveraging artificial intelligence, quantum physics, and robotics to accelerate pharmaceutical research.
Related Articles
All News →
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
Tempus AI Reports 75% Revenue Growth in Q1 2026, Driven by Genomics and Data Licensing
Tempus AI has reported first-quarter 2026 revenue of $255 million, a 75% increase year-over-year, driven by strong growth in its genomics testing and data licensing segments as the company continues its post-IPO expansion.
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical Foundation Model
Aidoc has closed a $150 million Series E round led by Goldman Sachs, with participation from existing investors, to scale its CARE clinical AI foundation model and expand its presence in radiology and emergency medicine workflows globally.
Recursion Pharmaceuticals Advances Three AI-Discovered Drug Candidates Into Phase 2 Trials
Recursion Pharmaceuticals has announced that three drug candidates identified through its AI-powered drug discovery platform have advanced into Phase 2 clinical trials, marking a significant milestone for the AI-native pharmaceutical development model.